696 results on '"Pinter, Matthias"'
Search Results
102. The value of [11C]-acetate PET and [18F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab
103. Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply.
104. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab
105. Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study
106. The Sequential Application of Baveno VII Criteria and VITRO Score Improves Diagnosis of Clinically Significant Portal Hypertension
107. Clinical significance of substantially elevated von Willebrand factor antigen levels in patients with advanced chronic liver disease
108. Targeting DNA repair to enhance the efficacy of sorafenib in hepatocellular carcinoma
109. NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy
110. Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
111. Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy
112. Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease
113. Reply to: “The CRAFITY score: a promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations”
114. Carvedilol Achieves Higher Hemodynamic Response and Lower Rebleeding Rates Than Propranolol in Secondary Prophylaxis
115. Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
116. On treatment alpha-fetoprotein reductions predict immunotherapy efficiency in patients with hepatocellular carcinoma
117. The effects of apurimic/apirimidinic endonuclease 1 as a sensitizer to sorafenib in hepatocellular carcinoma
118. Immunotherapy for hepatocellular carcinoma in a patient with hepatitis B virus and hepatitis delta virus coinfection
119. Progression patterns and therapeutic sequencing following immune checkpoint inhibition for HCC: an observational study
120. Sarcopenia impairs survival and treatment efficacy in patients with hepatocellular carcinoma undergoing immunotherapy
121. The alpha-1 antitrypsin Pi*Z allele is an independent risk factor for liver transplantation/death in patients with advanced chronic liver disease
122. Substantial reduction of the diagnostic grey zone of the Baveno-VII CSPH criteria by sequential consideration of VITRO
123. Prognostic impact of variants in TM6SF2 and MBOAT7 in patients who have progressed to advanced chronic liver disease
124. Disturbances in sodium and chloride hemostasis predict outcome in stable and critically-ill patients with cirrhosis-not two sides of the same coin
125. Carvedilol is associated with superior hemodynamic response and rebleeding rates in comparison to propranolol in secondary prophylaxis of variceal bleeding
126. Factor VIII/protein C ratio does not reflect coagulation but is linked to pathophysiological mechanisms driving disease progression in patients with advanced chronic liver disease
127. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study
128. The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma
129. Novel imaging feature in patients with porto-sinusoidal vascular disorder (PSVD)-radiological evaluation guiding diagnosis
130. Portal hypertension-associated clinical features in patients with primary biliary cholangitis are of distinct prognostic value
131. Changing Epidemiological Trends of Hepatobiliary Carcinomas in Austria 2010–2018
132. OS-079-YI Development and validation of the CABLE score to estimate individual prognosis of patients with hepatocellular carcinoma treated with 1L atezolizumab and bevacizumab
133. OS-078-YI Hepatic decompensation as an aetiology-dependent determinant of mortality in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
134. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score
135. Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience
136. Efficacy and safety of atezolizumab and bevacizumab in the real-world treatment of advanced hepatocellular carcinoma: Experience from four tertiary centers
137. Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD
138. Reply to: “The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy”
139. Reply to: “Prognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet?”
140. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease
141. Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers
142. sj-docx-2-tam-10.1177_17588359221080298 ��� Supplemental material for Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience
143. sj-docx-1-tam-10.1177_17588359221080298 ��� Supplemental material for Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience
144. Real-world use of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis.
145. Outcomes of beta blockers (BB) in hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitors (ICIs).
146. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score
147. Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience
148. The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma
149. Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis
150. Mesalazine and thymoquinone attenuate intestinal tumour development in Msh2loxP/loxP Villin-Cre mice
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.